 GAITHERSBURG, Md., June 29, 2021 GLOBE NEWSWIRE -- Altimmune, Inc. Nasdaq: ALT, a clinical-stage biopharmaceutical company, today provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The Company also provided an update on its T-COVID Phase 12 clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19. 